Welcome to our dedicated page for HUTCHMED (China) SEC filings (Ticker: HMDCF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for HUTCHMED (China) Limited (HMDCF) on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign issuer under the Securities Exchange Act of 1934. HUTCHMED (China) Limited indicates that it files annual reports on Form 20-F, the standard format for many non-U.S. companies whose securities trade in U.S. markets.
In addition to annual reports, the company furnishes current reports on Form 6-K. One such Form 6-K includes an exhibit index listing a press release relating to an R&D updates presentation. This illustrates how HUTCHMED (China) Limited uses Form 6-K to provide interim information, press releases, and event-related materials to investors between its annual filings.
On this page, users can review the sequence of HMDCF filings, including Form 20-F annual reports when available and Form 6-K current reports. Stock Titan enhances these documents with AI-powered summaries that explain the key points of each filing in plain language, helping readers understand the main topics, such as the nature of a press release or the type of update being furnished.
The filings feed is updated as new documents are accepted by the SEC’s EDGAR system, allowing investors to see when HUTCHMED (China) Limited submits additional 6-K reports or other forms. Users can also identify filings that may relate to topics such as R&D updates, corporate communications, and other matters disclosed through exhibits attached to Form 6-K.
HUTCHMED (China) Ltd director Tony Shu Kam Mok filed an initial ownership report on Form 3. He reported beneficial ownership of 27,341 American depositary shares. Each American depositary share represents 5 ordinary shares of HUTCHMED.
HUTCHMED (China) Ltd director Wong Tak Wai has filed a Form 3, which is an initial statement of insider ownership. The filing lists him as a director but shows no share transactions and no reported buy, sell, acquire, or dispose activity at this time.
HUTCHMED (China) Ltd director Eldar Dan filed an initial ownership report listing his direct equity stake in the company. He reported holding 19,000 ordinary shares and 26,332 American depositary shares. A footnote states that each American depositary share represents 5 ordinary shares. The filing does not show any new buy or sell transactions, only existing holdings.
HUTCHMED (China) Ltd reported that Hu Chaohong is a director and a reporting person on a Form 3. The data provided shows no insider transactions, with zero shares listed as bought, sold, acquired, or disposed in this filing snapshot.
HUTCHMED (China) Ltd director Edith Shih has filed an initial ownership report showing her equity stake in the company. She reports direct holdings of 700,000 ordinary shares and 100,000 American depositary shares. Each American depositary share represents 5 ordinary shares.
HUTCHMED is withdrawing cancer drug TAZVERIK® from Greater China after safety concerns emerged in a major global study. Ipsen, which holds the marketing authorization, is voluntarily withdrawing TAZVERIK in the US following data from the SYMPHONY-1 trial showing secondary blood cancers that may outweigh benefits.
HUTCHMED’s subsidiary has begun market withdrawal and product recalls in the Chinese mainland, Hong Kong and Macau, and has stopped all active tazemetostat clinical trials locally. Healthcare providers and pharmacies have been told to cease prescribing and dispensing the drug, and trial sites must stop using it.
TAZVERIK had conditional approval in China for follicular lymphoma, with ongoing obligations tied to foreign safety signals. HUTCHMED reports that the withdrawal is not expected to affect its overall financial guidance; 2025 TAZVERIK sales were US$2.5 million.
HUTCHMED (China) Limited reports that Independent Non-executive Director Professor Mok Shu Kam, Tony will retire from the Board at the annual general meeting on May 12, 2026 and will not seek re-election. He has served for more than eight years, approaching the nine-year cap on independent director tenure under Hong Kong Listing Rules.
At the conclusion of the meeting, he will cease to be an Independent Non-executive Director and step down from his roles as chairman and member of the Company’s board committees, including the Nomination and Technical Committees. The Board has approved changes to the composition of board committees and the Senior and Lead Independent Non-executive Director role, effective from the end of the meeting, subject to shareholder re-election of the relevant directors. Professor Mok has confirmed he has no disagreement with the Board and that there are no other matters needing shareholder attention regarding his retirement.
HUTCHMED reported 2025 full-year results with revenue of $548.5 million, down 13% from 2024, and net income of $456.9 million, up sharply from $37.7 million. Profit was boosted by a $415.8 million gain on divesting part of SHPL, alongside lower operating expenses.
Oncology/Immunology consolidated revenue fell 21% to $285.5 million, but total in‑market oncology sales grew 5% to $524.7 million, led by 26% FRUZAQLA® growth. Cash, cash equivalents and short-term investments rose to $1.37 billion, and 2026 Oncology/Immunology revenue guidance is $330–$450 million.
HUTCHMED (China) Limited files its annual report detailing 2025 results and key risks around its China-focused oncology business. The company is a Cayman holding structure with operations run mainly through PRC subsidiaries and 872,327,620 ordinary shares outstanding as of December 31, 2025.
The report highlights dependence on three approved oncology drugs and a large pipeline still in development, alongside heavy R&D spending and a 2025 operating cash outflow of $64.7 million after positive operating cash flows in 2023 and 2024. Equity earnings from its Shanghai Hutchison Pharmaceuticals stake fell 51.3% to $22.7 million in 2025 after divesting 45% of that business.
HUTCHMED flags substantial legal and operational risks from PRC oversight, data and cybersecurity rules, the Holding Foreign Companies Accountable Act, and evolving Chinese approval requirements for offshore offerings. It notes FX controls and PRC dividend restrictions, has never paid dividends, and warns it may need substantial additional capital, which could dilute shareholders or add debt.
HUTCHMED has begun a global Phase I/IIa clinical trial of HMPL-A580, its second next-generation Antibody-Targeted Therapy Conjugate (ATTC), in patients with unresectable, advanced or metastatic solid tumors in China and the US. The first patient was dosed on March 4, 2026.
HMPL-A580 links a highly selective PI3K/PIKK small-molecule inhibitor to an anti-EGFR antibody, aiming to exploit synergy between PAM pathway inhibition and EGFR blockade. The study’s dose-escalation phase will determine the recommended dose, followed by expansion cohorts to further assess safety and preliminary anti-tumor activity.